Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Economic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative

Authors de Oliveira, Wijeysundera H, Tobe, Moy Lum-Kwong M, Von Sychowski S, Wang, Tu J, Krahn M 

Received 28 April 2012

Accepted for publication 12 July 2012

Published 13 November 2012 Volume 2012:4 Pages 323—336

DOI https://doi.org/10.2147/CEOR.S33390

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2



Claire de Oliveira,1,2 Harindra C Wijeysundera,2,3 Sheldon W Tobe,4 Margaret Moy Lum-Kwong,5 Shirley Von Sychowski,5 Xuesong Wang,6 Jack V Tu,6 Murray D Krahn2,7

1
University Health Network, Toronto, ON, Canada; 2Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada; 3Schulich Heart Centre, Division of Cardiology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; 4Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; 5Heart and Stroke Foundation of Ontario, Toronto, ON, Canada; 6Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; 7Department of Medicine and Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

Objectives: Hypertension is suboptimally treated in primary care settings. We evaluated the cost-effectiveness of the Heart and Stroke Foundation of Ontario's Hypertension Management Initiative (HMI), an interdisciplinary, evidence-informed chronic disease management model for primary care that focuses on improving blood pressure management and control by primary care providers and patients according to clinical best practice guidelines.
Methods: The perspective of our analysis was that of the Ontario Ministry of Health and Long-Term Care with a lifetime horizon and 5% annual discount rate. Using data from a prospective cohort study from the HMI, we created two matched groups: pre-HMI (standard care), and post-HMI (n = 1720). For each patient, we estimated the 10-year risk of cardiovascular disease (CVD) using the Framingham risk equation and life expectancy from life tables. Long-term health care costs incurred with physician visits, acute and chronic care hospitalizations, emergency department visits, same-day surgeries, and medication use were determined through linkage to administrative databases, using a bottom-up approach.
Results: The HMI intervention was associated with significant reductions in systolic blood pressure (126 mmHg vs 134 mmHg with standard care; P-value < 0.001). These improvements were associated with a reduction in the 10-year risk of CVD (9.5% risk vs 10.7% in standard care; P-value < 0.001) and a statistically significant improvement in discounted life expectancy (9.536 years vs 9.516 in standard care; P-value < 0.001). The HMI cohort had a discounted mean lifetime cost of $22,884 CAD vs $22,786 CAD for standard care, with an incremental cost-effectiveness ratio of $4939 CAD per life-year gained.
Conclusion: We found that the HMI is a cost-effective means of providing evidence-informed, chronic disease management in primary care to patients with hypertension.

Keywords: hypertension, economic evaluation, cardiovascular disease

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.